Recursion Pharmaceuticals (RXRX) Earnings Date, Estimates & Call Transcripts $6.04 -0.23 (-3.67%) (As of 11/20/2024 ET) Add Compare Share Share Earnings Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends Recursion Pharmaceuticals Latest Earnings SummaryUpcoming Q4 Earnings DateFeb. 25EstimatedActual EPS (Nov. 6) -$0.34 Missed By -$0.01 Consensus EPS (Nov. 6) -$0.33 Recursion Pharmaceuticals posted Q3 2024 earnings on November 6, 2024, reporting an EPS of -$0.34, which missed the consensus estimate of -$0.33 by $0.01. Quarterly revenue rose 147.6% year-over-year to $26.08 million, above analysts' expectations of $12.62 million. With a trailing EPS of -$1.53, Recursion Pharmaceuticals' earnings are expected to grow next year, from ($1.56) to ($1.42) per share. SEC 10-Q/10-K FilingRXRX Upcoming EarningsRecursion Pharmaceuticals' next earnings date is estimated for Tuesday, February 25, 2025, based off prior year's reporting schedules. Get Recursion Pharmaceuticals Earnings Alerts Want to stay updated on the latest earnings announcements and upcoming reports? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Recursion Pharmaceuticals and other key companies, straight to your inbox. Enter your email to sign up for newsletter Sign Up Skip Charts & View Estimated and Actual Earnings DataRXRX Earnings Estimates and Actuals by QuarterEarnings Estimates and Acutals by Quarter Chart DescriptionThe chart below shows up to four years of a company's earnings history. The dark blue line represents the company's actual earnings per share. The light blue area represents the range of Wall Street analysts' earnings estimates for each quarter.RXRX Estimated and Actual Revenue by QuarterEstimated Revenue and Actual Revenue by Quarter Chart DescriptionThe chart below shows up to four years of a company's revenue history. The dark blue line represents the company's actual revenue. The light blue line represents the company's estimated revenue based on the consensus of Wall Street analysts for each quarter. Ad DarwinNew Year, New Opportunity! 2 AI Stocks Under $10 Ready to SoarAs we step into 2025, artificial intelligence (AI) stocks continue to dominate headlines, and now is the perfect moment to position yourself for the coming year’s potential. Our latest research has uncovered two must-buy AI stocks currently trading under $10/share – an affordable entry with promising growth potential. These stocks are flying under the radar, but it’s only a matter of time before they gain mainstream attention.👉 Click here to access your FREE report now! Recursion Pharmaceuticals Analyst EPS EstimatesQuarterNumber of EstimatesLow EstimateHigh EstimateAverage EstimateQ1 20242-$0.41-$0.33-$0.37Q2 20242-$0.41-$0.33-$0.37Q3 20242-$0.41-$0.35-$0.38Q4 20242-$0.83-$0.33-$0.58FY 20248($2.06)($1.34)($1.70) Recursion Pharmaceuticals Earnings History by Quarter Custom Range 3 Months 6 Months Year-to-Date 1 Year 2 Years 3 Years 5 Years 10 Years Time Frame * Start Date * End Date Export to Excel DateQuarterConsensus EstimateReported EPSBeat/MissGAAP EPSRevenue EstimateActual RevenueLinks 2/25/2025(Estimated)------- 11/6/2024Q3 2024-$0.33-$0.34 -$0.01-$0.34$12.62M$26.08M 8/8/2024Q2 2024-$0.35-$0.40 -$0.05-$0.40$11.96M$14.42M 5/9/2024Q1 2024-$0.43-$0.39+$0.04-$0.39$11.10M$13.80M 2/27/2024Q4 2023-$0.46-$0.40+$0.06-$0.40$12.37M$10.89M 11/9/2023Q3 2023-$0.38-$0.43 -$0.05-$0.43$12.20M$10.53M 8/8/2023Q2 2023-$0.38-$0.38--$0.38$10.43M$11.02M Get the Latest News and Ratings for RXRX and Related StocksEnter your email address below to receive the latest news and analysts' ratings for Recursion Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. 5/8/2023Q1 2023-$0.35-$0.34+$0.01-$0.34$15.93M$12.13M 2/27/2023Q4 2022-$0.15-$0.31 -$0.16-$0.31$66.68M$13.68M Recursion Pharmaceuticals Earnings - Frequently Asked Questions When is Recursion Pharmaceuticals's earnings date? Recursion Pharmaceuticals has not confirmed its next earnings publication date, but the company's estimated earnings date is Tuesday, February 25th, 2025 based off last year's report dates. Learn more on RXRX's earnings history. Did Recursion Pharmaceuticals beat their earnings estimates last quarter? In the previous quarter, Recursion Pharmaceuticals (NASDAQ:RXRX) missed the analysts' consensus estimate of ($0.33) by $0.01 with a reported earnings per share (EPS) of ($0.34). Learn more on analysts' earnings estimate vs. RXRX's actual earnings. How can I view Recursion Pharmaceuticals's earnings report? Recursion Pharmaceuticals's earnings report can be found in their filing with the SEC. View SEC filing How much revenue does Recursion Pharmaceuticals generate each year? Recursion Pharmaceuticals (NASDAQ:RXRX) has a recorded annual revenue of $44.58 million. How much profit does Recursion Pharmaceuticals generate each year? Recursion Pharmaceuticals (NASDAQ:RXRX) has a recorded net income of -$328.07 million. RXRX has generated -$1.53 earnings per share over the last four quarters. What is Recursion Pharmaceuticals's EPS forecast for next year? Recursion Pharmaceuticals's earnings are expected to grow from ($1.56) per share to ($1.42) per share in the next year. ` More Earnings Resources from MarketBeat Related Companies SDGR Earnings Date RCUS Earnings Date RLAY Earnings Date ABCL Earnings Date EXAI Earnings Date EBS Earnings Date ABSI Earnings Date LEGN Earnings Date ELAN Earnings Date BPMC Earnings Date Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Earnings By Country U.S. Earnings Reports Canadian Earnings Reports U.K. Earnings Reports Latest Articles Alibaba Stock: Why Earnings Make It a Buy Despite the Recent DipMercadoLibre Down 23% After Missed Earnings: Time to Buy the Dip?Roblox Stock Soars 22% After Q3 Earnings – A Turning Point Ahead?Apple Earnings - When Really Good Just Isn’t Good Enough Roblox Stock Set for More Gains After Strong Earnings ReportAmazon: Why Analysts Think It's a Solid Buy Ahead of EarningsLam Research Proves Analysts Wrong with a Strong Earnings Report New Year, New Opportunity! 2 AI Stocks Under $10 Ready to Soar (Ad)As we step into 2025, artificial intelligence (AI) stocks continue to dominate headlines, and now is the perfect moment to position yourself for the coming year’s potential. Our latest research has uncovered two must-buy AI stocks currently trading under $10/share – an affordable entry with promising growth potential. These stocks are flying under the radar, but it’s only a matter of time before they gain mainstream attention.👉 Click here to access your FREE report now! This page (NASDAQ:RXRX) was last updated on 11/21/2024 by MarketBeat.com Staff From Our PartnersThe Crypto That’s Making Wall Street SweatThe Crypto Wall Street Is Desperate to Hide It's happening now, right under everyone's radar. Big tech gian...Crypto 101 Media | SponsoredMissed Nvidia? Watch this ASAPThis little-known project that Bill Gates has been quietly working on that’s about to unleash an AI breakthrou...Brownstone Research | SponsoredMusk’s new company could top a trillion?The investment legend who predicted the rise of Bitcoin, Facebook and streaming services like Netflix… Just...Paradigm Press | Sponsored24/7 Automated Profits in CryptoWhat if you could make consistent daily profits in crypto with minimal effort? Beyond trading lies a vast w...Crypto Swap Profits | SponsoredCrypto’s next big bull run?Juan Villaverde may be America’s top crypto expert. And he says something big is coming for crypto – on Nov...Weiss Ratings | Sponsored“This Changes Everything” - Trump Hands Millions Massive IRS GiftNow it's your time to return the favor by taking advantage of this tax "revenge loophole." Because even as ...Colonial Metals | SponsoredTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT abou...Timothy Sykes | SponsoredElon knows the truth, which is why they want him silencedElon Musk is one of mankind’s greatest innovators. But for all his visionary prowess and contributions to h...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Recursion Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Recursion Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free RXRX Stock Alerts